Oncotarget · 2016 · 24 citations · 23 references
MedicineOtolaryngologyNeck OncologyOtolaryngologic SurgerySalivary Gland DisordersMalignant Salivary Gland TumorsSalivary Duct DisordersSalivary Gland CancerSalivary Gland MalignanciesSalivary Gland PathologySalivary GlandsAmplificationMalignant Salivary Gland LesionsParotid Gland CarcinomaSalivary Duct Neoplasms
// Inga Grünewald 1 , Marcel Trautmann 1 , Alina Busch 2 , Larissa Bauer 1 , Sebastian Huss 1 , Petra Schweinshaupt 3 , Claudia Vollbrecht 3, 4 , Margarete Odenthal 3 , Alexander Quaas 3 , Reinhard Büttner 3 , Moritz F. Meyer 5 , Dirk Beutner 5 , Karl-Bernd Hüttenbrink 5 , Eva Wardelmann 1 , Markus Stenner 2 , Wolfgang Hartmann 1 1 Department of Pathology, University Hospital Muenster, Muenster, Germany 2 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Muenster, Muenster, Germany 3 Institute of Pathology, University Hospital Cologne, Cologne, Germany 4 Current address: Institute of Pathology, Charité University Hospital Berlin, Berlin, Germany 5 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Cologne, Cologne, Germany Correspondence to: Inga Grünewald, email: inga.gruenewald@ukmuenster.de Keywords: salivary gland carcinoma, p53, MDM2, CDK4, HMGA2 Received: February 15, 2016 Accepted: September 12, 2016 Published: September 20, 2016 ABSTRACT Salivary duct carcinoma (SDC) is an aggressive adenocarcinoma of the salivary glands associated with poor clinical outcome. SDCs are known to carry TP53 mutations in about 50%, however, only little is known about alternative pathogenic mechanisms within the p53 regulatory network. Particularly, data on alterations of the oncogenes MDM2 and CDK4 located in the chromosomal region 12q13-15 are limited in SDC, while genomic rearrangements of the adjacent HMGA2 gene locus are well documented in subsets of SDCs. We here analyzed the mutational status of the TP53 gene, genomic amplification of MDM2, CDK4 and HMGA2 rearrangement/amplification as well as protein expression of TP53 (p53), MDM2 and CDK4 in 51 de novo and ex pleomorphic adenoma SDCs. 25 of 51 cases were found to carry TP53 mutations, associated with extreme positive immunohistochemical p53 staining levels in 13 cases. Three out of 51 tumors had an MDM2 amplification, one of them coinciding with a CDK4 amplification and two with a HMGA2 rearrangement/amplification. Two of the MDM2 amplifications occurred in the setting of a TP53 mutation. Two out of 51 cases showed a CDK4 amplification, one synchronously being MDM2 amplified and the other one displaying concurrent low copy number increases of both, MDM2 and HMGA2 . In summary, we here show that subgroups of SDCs display genomic amplifications of MDM2 and/or CDK4 , partly in association with TP53 mutations and rearrangement/amplification of HMGA2 . Further research is necessary to clarify the role of chromosomal region 12q13-15 alterations in SDC tumorigenesis and their potential prognostic and therapeutic relevance.
23
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano et al. · The Lancet Oncology · 2012 · 563 citations
Medicine, Cancer Biology, Oncology +16